Company news

Mesoblast Limited news in 2019

Mesoblast Limited's news releases, calls and decks from 2019, newest first.

View company

DMC Completes Final Review of Phase 3 Heart Failure Trial

December 17, 2019

CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)

December 16, 2019

CHF P3 Trial Accrues Sufficient Primary Endpoint Events

December 16, 2019

MSB Provides Q1 Financial Results and Operational Highlights

November 25, 2019

MSB and Lonza Enter GVHD Commercial Manufacturing Agreement

October 16, 2019

Mesoblast Raises A$75 Million

October 3, 2019

Grunenthal and MSB Enter Strategic Partnership for Back Pain

September 9, 2019

Mesoblast Reports on Annual Results

August 29, 2019

FDA Guidance on Clinical Pathway for LVAD Market Application

August 27, 2019

Appendix 4C - Quarterly, Strong Commercialization Revenues

July 31, 2019

Circulation Research Highlights MSB Heart Failure Therapy

July 24, 2019

FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs

June 24, 2019

MSB Expands JCR Partnership To Brain Disease In Newborns

June 11, 2019

MSB Provides Q3 Financial Results and Operational Highlights

May 30, 2019

Mesoblast Initiates Rolling Submission of BLA for GvHD

May 29, 2019

MoU for Confirmatory Trial for GI Bleeding in LVAD Patients

March 26, 2019

MSB Licensee Files For Skin Disease Marketing Approval

March 24, 2019

MSB Draws US$15 Million From Existing Facility

January 13, 2019

P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment

January 6, 2019

Decks in 2019